Cargando…

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

Dementia with Lewy bodies (DLB) and Parkinson's Disease (PD) are common causes of motor and cognitive deficits and are associated with the abnormal accumulation of alpha-synuclein (α-syn). This study investigated whether passive immunization with a novel monoclonal α-syn antibody (9E4) against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masliah, Eliezer, Rockenstein, Edward, Mante, Michael, Crews, Leslie, Spencer, Brian, Adame, Anthony, Patrick, Christina, Trejo, Margarita, Ubhi, Kiren, Rohn, Troy T., Mueller-Steiner, Sarah, Seubert, Peter, Barbour, Robin, McConlogue, Lisa, Buttini, Manuel, Games, Dora, Schenk, Dale
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084838/ https://www.ncbi.nlm.nih.gov/pubmed/21559417 http://dx.doi.org/10.1371/journal.pone.0019338

Ejemplares similares

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
por: Rockenstein, Edward, et al.
Publicado: (2014)

A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick’s Disease and Fronto-Temporal Tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
por: Overk, Cassia R, et al.
Publicado: (2014)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
por: Xu, Jiqing, et al.
Publicado: (2016)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha‐synuclein in oligodendrocytes
por: Tank, Jens, et al.
Publicado: (2014)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
por: Crews, Leslie, et al.
Publicado: (2010)

Differential Effects of UCHL1 Modulation on Alpha-Synuclein in PD-Like Models of Alpha-Synucleinopathy
por: Cartier, Anna E., et al.
Publicado: (2012)

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity
por: Price, Diana L., et al.
Publicado: (2010)

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
por: Bender, Andreas, et al.
Publicado: (2013)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
por: Kim, Changyoun, et al.
Publicado: (2018)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
por: Mandler, Markus, et al.
Publicado: (2015)

Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein
por: Sekigawa, Akio, et al.
Publicado: (2012)

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021)

APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
por: Crews, Leslie, et al.
Publicado: (2009)

Role of Synucleins in Alzheimer’s Disease
por: Crews, Leslie, et al.
Publicado: (2009)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
por: Valera, Elvira, et al.
Publicado: (2015)

Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease
por: Crews, L, et al.
Publicado: (2011)

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
por: Bae, Eun-Jin, et al.
Publicado: (2018)

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity
por: Fields, Jerel A., et al.
Publicado: (2016)

The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
por: Marschallinger, Julia, et al.
Publicado: (2020)

Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice
por: Leitão, André D.G., et al.
Publicado: (2023)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer
por: Fields, Jerel, et al.
Publicado: (2013)

Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders
por: Crews, Leslie, et al.
Publicado: (2011)

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
por: Spencer, Brian, et al.
Publicado: (2014)

Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models
por: Iba, Michiyo, et al.
Publicado: (2020)

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
por: Hall, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gghh3r84b6v4nk8pmjb65fm33a